Dipneo opens a round via Capital Cell to raise 300,000 Euros

Dipneo opens a round via Capital Cell to raise 300,000 Euros

  • The investment campaign aims to raise capital to finalize the commercial prototype of a groundbreaking cardiopulmonary resuscitation device and begin regulatory procedures.
  • With a valuation of €2.4 million, Dipneo was established by Eurecat Technology Centre and Mobile World Capital Barcelona.
  • The new CPR system, patented by Eurecat, is expected to significantly impact out-of-hospital settings, hospital environments, and cardio-protected areas.

Dipneo, a start-up founded by the Eurecat Technology Centre and Mobile World Capital Barcelona, has initiated an investment round via Capital Cell, a crowdfunding platform specializing in biotechnology and health. The campaign seeks to raise €300,000 to accelerate the development of an innovative cardiopulmonary resuscitation (CPR) device.

With a valuation of €2.4 million, Dipneo plans to use the funds to complete the commercial prototype and start the necessary regulatory procedures to bring the device to market. Unlike current airbag-based insufflators, this new device operates autonomously and hands-free.

The Dipneo device is based on a system patented by Eurecat, which allows autonomous air insufflation, making it suitable for both non-expert users and professionals.

According to Dipneo’s CEO, Xavier Castells, “Our goal is to launch the first version of the device by 2026,” with projected sales of €2.5 million in 2027.

Dipneo aims to complement Automated External Defibrillators (AEDs), targeting a market valued at €4.2 billion, with an expected annual growth rate of 8.8%, says Dipneo’s CTO, biomedical engineer Julio Díaz.

Dipneo will impact various settings, including out-of-hospital emergencies, primary care centres, emergency rooms, transit rescues, and cardio-protected areas such as elderly residences, businesses, sports facilities, and municipal buildings, explains co-founder Ferran Soldevila, responsible for industrial technology valorisation at Eurecat.

Addressing a Critical Health Issue: Out-of-Hospital Cardiorespiratory Arrests

Out-of-hospital cardiorespiratory arrests affect approximately 700,000 people annually in Europe, with a survival rate of just 10%. CEO Xavier Castells notes, “Increasing the survival rate to 45% requires prompt and effective CPR.”

Based in Barcelona, Dipneo is led by Xavier Castells, CEO, who has extensive experience as a CFO and advisor in various companies and start-ups, and is an investor in the health sector; and Julio Díaz, CTO, a biomedical engineer with expertise in resuscitation devices. The team also includes a committee of experts featuring Dr. Marc Bausili, an anaesthesiology and resuscitation specialist and entrepreneur, and David Osorio, director of the medical emergencies area of the Red Cross in Catalonia.

Stay up to date about everything

Subscribe to stay up to date with the latest content from Mobile World Capital Barcelona.